High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages

  De Biase, Dario ^a   Cesari, Valentina ^a   Visani, Michela ^a   Casadei, Gian Piero ^b   Cremonini, Nadia ^c   Gandolfi, Greta ^d   Sancisi, Valentina ^d   Ragazzi, Moira ^d   Pession, Annalisa ^a   Ciarrocchi, Alessia ^d   Tallini, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Presidio Ospedaliero di Imola   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMINO ACID SUBSTITUTION; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETIC HETEROGENEITY; GLUTAMIC ACID; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; VALINE; YOUNG ADULT;

EID: 84905867190     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4389     Document Type: Article

References (28)

1. El-Osta H, Falchook G, Tsimberidou A, et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PloS One. 2011;6:e25806.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
3. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
4. Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136:440-444.
5. Kimura ET, NikiforovaMN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63:1454-1457.
6. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005; 65:4238-4245.
7. Guerra A, Sapio MR, Marotta V, et al. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:517-524.
8. Gandolfi G, Sancisi V, Torricelli F, et al. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab. 2013;98:E934-E942.
9. Altimari A, de Biase D, De Maglio G, et al. 454 Next generationsequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routineKRASmutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther. 2013;6:1057-1064.
10. de Biase D, Visani M, Baccarini P, et al. Next generation sequencing improves the accuracy ofKRASmutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS One. 2014;9:e87651.
11. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98: E1852-E1860.
12. Morandi L, de Biase D, Visani M, et al. Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation. PLoS One. 2012;7:e36084.
13. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.
14. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 2009;4:e7464.
15. Ghossein RA, Katabi N, Fagin JA. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab. 2013;98:E1414-E1421.
16. Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol. 2005;42:405-426.
17. Guerra A, Fugazzola L, Marotta V, et al. A high percentage of BRAFV600Ealleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab. 2012;97:2333-2340.
18. VogelsteinB, PapadopoulosN, VelculescuVE, ZhouS, DiazLAJr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-1558.
19. Yancovitz M, Litterman A, Yoon J, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One. 2012;7:e29336.
20. Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol. 2009;131:678-682.
21. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008;99:929-935.
22. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77-88.
23. Buob D, Fauvel H, Buisine MP, et al. The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection. Dig Dis Sci. 2012;57:1271-1280.
24. Mancuso A, Sollami R, Recine F, Cerbone L, MacciomeiMC, Leone A. Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy. J Clin Oncol. 2010;28:e756-e758.
25. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481:306-313.
26. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations inprimarycolorectaladenocarcinomasandtheir corresponding metastases. Clin Cancer Res. 2010;16:790-799.
27. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522-2529.
28. Saint-Jean M, Quereux G, Nguyen JM, et al. Is a single BRAF wildtype test sufficient to exclude melanoma patients from vemurafenib therapy? J Invest Dermatol. 2014;134(5):1468-1470.